Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement

Lucid Diligence Brief: SiranBio and GSK SA030 Licensing Agreement Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal

Lucid Diligence Brief: Arrowhead ARO-PNPLA3 licensed to Madrigal Professional…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Latus Bio $97 million Series A

Lucid Diligence Brief: Latus Bio $97 million Series A Professional audiences…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: UCB acquisition of Candid Therapeutics

Lucid Diligence Brief: UCB acquisition of Candid Therapeutics Professional…


Artificial_Intelligence

AI in Healthcare and Digital Health Today—May 4, 2026

This week’s AI in Healthcare and Digital Health update highlights…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Axoft $55 million Series A

Lucid Diligence Brief: Axoft $55 million Series A Professional audiences only.…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic partnership

Lucid Diligence Brief: Greywolf Therapeutics and Genomics strategic……


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Teva to acquire Emalex Biosciences

Lucid Diligence Brief: Teva to acquire Emalex Biosciences Professional…


Lucid Diligence Brief - Tech

Lucid Diligence Brief: Profluent-Lilly AI-Designed Recombinase Partnership

Lucid Diligence Brief: Profluent-Lilly AI-Designed Recombinase Partnership…


Lucid Diligence Brief - BioPharma

Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics

Lucid Diligence Brief: Lilly to acquire Ajax Therapeutics Professional…


Artificial_Intelligence

AI in Healthcare and Digital Health Today—April 28, 2026

This week’s Artificial Intelligence and Digital Health update highlights…


Privacy Preference Center